OBJECTIVE: In lupus nephritis, tubulointerstitial inflammation (TII) is associated with in situ adaptive immune cell networks that amplify local tissue damage. Since conventional therapy appears ineffective for severe TII, and these patients often progress to renal failure, understanding in situ mechanisms might reveal new therapeutic targets. This study was undertaken to assess whether dysregulated apoptotic regulators maintain local adaptive immunity and drive inflammation in TII. METHODS: This study utilized novel computational approaches that, when applied to multicolor confocal images, quantified apoptotic regulator protein expression in selected lymphocyte subsets. This approach was validated using laser-capture microdissection (LCM) coupled to quantitative polymerase chain reaction (qPCR). Furthermore, the consequences of dysregulated apoptotic mediator expression were explored in a murine model of lupus nephritis. RESULTS: Analyses of renal biopsy tissue from patients with lupus nephritis and those with mixed cellular renal allograft rejection revealed that the B cell lymphoma 2 protein (Bcl-2) was frequently expressed in infiltrating lymphocytes, whereas expression of myeloid cell leukemia 1 was low. In contrast, the reciprocal pattern of expression was observed in tonsil germinal centers. These results were consistent with RNA expression data obtained using LCM and qPCR. Bcl-2 was also highly expressed in tubulointerstitial infiltrates in (NZB × NZW)F1 (NZB/NZW) mice. Furthermore, treatment of NZB/NZW mice with ABT-199, a selective oral inhibitor of Bcl-2, prolonged survival and prevented proteinuria and development of TII in a lupus prevention model. Interestingly, glomerular immune complexes were partially ameliorated by ABT-199 treatment, and serum anti-double-stranded DNA antibody titers were unaffected. CONCLUSION: These data demonstrate that Bcl-2 is an attractive therapeutic target in patients with lupus nephritis who manifest TII.
OBJECTIVE: In lupus nephritis, tubulointerstitial inflammation (TII) is associated with in situ adaptive immune cell networks that amplify local tissue damage. Since conventional therapy appears ineffective for severe TII, and these patients often progress to renal failure, understanding in situ mechanisms might reveal new therapeutic targets. This study was undertaken to assess whether dysregulated apoptotic regulators maintain local adaptive immunity and drive inflammation in TII. METHODS: This study utilized novel computational approaches that, when applied to multicolor confocal images, quantified apoptotic regulator protein expression in selected lymphocyte subsets. This approach was validated using laser-capture microdissection (LCM) coupled to quantitative polymerase chain reaction (qPCR). Furthermore, the consequences of dysregulated apoptotic mediator expression were explored in a murine model of lupus nephritis. RESULTS: Analyses of renal biopsy tissue from patients with lupus nephritis and those with mixed cellular renal allograft rejection revealed that the B cell lymphoma 2 protein (Bcl-2) was frequently expressed in infiltrating lymphocytes, whereas expression of myeloid cell leukemia 1 was low. In contrast, the reciprocal pattern of expression was observed in tonsil germinal centers. These results were consistent with RNA expression data obtained using LCM and qPCR. Bcl-2 was also highly expressed in tubulointerstitial infiltrates in (NZB × NZW)F1 (NZB/NZW) mice. Furthermore, treatment of NZB/NZW mice with ABT-199, a selective oral inhibitor of Bcl-2, prolonged survival and prevented proteinuria and development of TII in a lupus prevention model. Interestingly, glomerular immune complexes were partially ameliorated by ABT-199 treatment, and serum anti-double-stranded DNA antibody titers were unaffected. CONCLUSION: These data demonstrate that Bcl-2 is an attractive therapeutic target in patients with lupus nephritis who manifest TII.
Authors: Silke F Fischer; Philippe Bouillet; Kristy O'Donnell; Amanda Light; David M Tarlinton; Andreas Strasser Journal: Blood Date: 2007-08-24 Impact factor: 22.113
Authors: Maria Angeles Ramos; Celestino Piñera; Maria Angeles Setién; Luis Buelta; Maria Angeles de Cos; Angel-Luis M de Francisco; Ramón Merino; Manuel Arias Journal: Nephrol Dial Transplant Date: 2003-05 Impact factor: 5.992
Authors: H M Bastian; J M Roseman; G McGwin; G S Alarcón; A W Friedman; B J Fessler; B A Baethge; J D Reveille Journal: Lupus Date: 2002 Impact factor: 2.911
Authors: Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer Journal: Nature Date: 2003-12-11 Impact factor: 49.962
Authors: Ricard Cervera; Munther A Khamashta; Josep Font; Gian Domenico Sebastiani; Antonio Gil; Paz Lavilla; Juan Carlos Mejía; A Olcay Aydintug; Hanna Chwalinska-Sadowska; Enrique de Ramón; Antonio Fernández-Nebro; Mauro Galeazzi; Merete Valen; Alessandro Mathieu; Frédéric Houssiau; Natividad Caro; Paula Alba; Manuel Ramos-Casals; Miguel Ingelmo; Graham R V Hughes Journal: Medicine (Baltimore) Date: 2003-09 Impact factor: 1.889
Authors: Vladimir M Liarski; Natalya Kaverina; Anthony Chang; Daniel Brandt; Denisse Yanez; Lauren Talasnik; Gianluca Carlesso; Ronald Herbst; Tammy O Utset; Christine Labno; Yahui Peng; Yulei Jiang; Maryellen L Giger; Marcus R Clark Journal: Sci Transl Med Date: 2014-04-02 Impact factor: 17.956
Authors: Joel D Leverson; Deepak Sampath; Andrew J Souers; Saul H Rosenberg; Wayne J Fairbrother; Martine Amiot; Marina Konopleva; Anthony Letai Journal: Cancer Discov Date: 2017-11-16 Impact factor: 39.397
Authors: Rebecca Abraham; Madeleine S Durkee; Junting Ai; Margaret Veselits; Gabriel Casella; Yuta Asano; Anthony Chang; Kichul Ko; Charles Oshinsky; Emily Peninger; Maryellen L Giger; Marcus R Clark Journal: J Clin Invest Date: 2022-07-01 Impact factor: 19.456
Authors: Andrew J Kinloch; Matthew D Cascino; Jian Dai; Rene S Bermea; Kichul Ko; Margaret Vesselits; Leonard L Dragone; Nirit Mor Vaknin; Maureen Legendre; David M Markovitz; Michael K Okoreeh; Michael J Townsend; Marcus R Clark Journal: Lupus Date: 2020-03-26 Impact factor: 2.911
Authors: Ping-Min Chen; Parker C Wilson; Justin A Shyer; Margaret Veselits; Holly R Steach; Can Cui; Gilbert Moeckel; Marcus R Clark; Joe Craft Journal: Sci Transl Med Date: 2020-04-08 Impact factor: 17.956